Merryman, R., Wallace, D., Redd, R., Walker, H., Tringale, R., Kats, V., Sagedahl, S., Vogiatzi, I., Zhang, M., Sumpena, E., Chuan, W., Sigmund, A., Ahn, I., Bessnow, A., Brown, J. R., Crombie, J., Davids, M. S., Fisher, D., Hahn, C., Jacobsen, E., Jacobson, C., Kim, A., LaCasce, A., Odejide, O., Parry, E., Qualls, D., Ryan, C., Sekar, A., Devata, S., Casulo, C., Maddocks, K., Murakami, M., Armand, P., Sawalha, Y. (2025). Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial. Blood. https://doi.org/10.1182/blood-2025-464